altM Raises $10.3 Million for Bio-Based Chemical Scale-Up

By Olivia Hart

Specialty chemicals startup altM raised $10.3 million in a Series A funding round, according to SiliconIndia. Rainmatter, backed by Zerodha, and Mela Ventures led the round. Existing investors Omnivore, Theia Ventures, Aureolis Ventures and Spectrum Impact also participated, alongside strategic angel investors; SiliconIndia disclosed neither a valuation nor individual investment amounts.

What does the Series A fund?

SiliconIndia said the capital will expand manufacturing capacity, strengthen research and development, support customer qualification programmes, and increase altM’s engineering and commercial teams. The funding should move altM from pilot-scale production to commercial manufacturing, but the report gave no allocation of the $10.3 million, production target or delivery date.

SiliconIndia quoted altM Co-founder and CEO Apoorv Garg: “Industrial manufacturing has relied on fossil carbon for more than a century. We are building a new source of industrial carbon from agricultural residue”. The report did not disclose yields, production costs or lifecycle findings for the proposed carbon source.

Takeaway: Investors are funding altM’s scale-up, while its commercial economics remain undisclosed.

How does altM turn agricultural residue into chemicals?

altM develops industrial chemicals using lignocellulosic biomass, including sugarcane bagasse and rice straw, according to SiliconIndia. The technology processes cellulose, hemicellulose and lignin to produce multiple chemicals from a single feedstock.

The company serves beauty and personal care, textiles, construction, packaging and consumer goods, according to the report. It focuses on bio-based alternatives to fossil-derived raw materials that help manufacturers reduce reliance on conventional industrial inputs.

SiliconIndia included no output volumes, customer names or performance data. The technology therefore has several stated end markets, but the cited material does not establish commercial uptake.

Takeaway: altM has identified several end markets, but the report provides no output, customer or performance data.

How far has altM progressed?

altM raised a $3.5 million seed round in 2023, according to SiliconIndia. Since then, it established an integrated research and pilot manufacturing facility in Bengaluru, combining laboratory research, demonstration manufacturing and pilot production.

According to SiliconIndia, altM took six molecules to demonstration scale and selected three for pilot plant production. The company also expanded its laboratory footprint nearly fivefold in less than two years.

altM is preparing to commercialize a lignin-derived SPF booster for suncare products, a cellulose-based rheology modifier, and bio-derived ferulic acid for cosmetics and personal care formulations. SiliconIndia gave no launch dates, prices or contracted volumes, so the cited material does not establish that commercial sales have begun.

Takeaway: altM has advanced molecules toward pilot production, while its named products remain at the pre-commercialization stage in the report.

What must the Series A prove?

The latest investment will support altM’s transition toward commercial-scale manufacturing and expand its ability to supply bio-based materials to industrial customers, according to SiliconIndia. That makes production scale the central operating test for this round.

Mela Ventures Managing Partner Krishnakumar N said: “Solving DeepTech problems involves research and understanding interplay of multiple areas. altM is tackling one of the hardest problems in industrial chemistry which is creating new age materials that can match the performance of fossil-derived inputs while fundamentally changing where their carbon comes from”. That claim sets a high bar for comparison.

SiliconIndia did not include performance benchmarks, independent validation, production economics or a timeline for customer qualification. The cited material therefore leaves the investor’s central claim untested.

The $10.3 million round will fund capacity and staffing for that transition, but it does not by itself resolve scale, margin or customer conversion. SiliconIndia also provided no revenue, profitability, headcount or capacity figures, leaving readers without a clear view of altM’s remaining capital needs.

Takeaway: altM’s next proof point is qualified, repeatable supply at disclosed scale and cost.